SLC1A2 and depressive disorder: •The new evolving potential drug targets for depression treatment are the NMDA-glutamatergic receptor as antagonist or inverse agonist or partial agonist; metabotropic glutamatergic receptors as positive or negative modulator; excitatory amino acid transporter-2 (EAAT-2) as a reuptake enhancer; and as a terminal presynaptic glutamate release inhibitor.